Inhibiting complement activation on cells at the step of C3 cleavage

Vaccine

Volumn 26, Issue SUPPL. 8, 2008, Pages

  Liszewski, M Kathryn ^a   Fang, Celia J ^b   Atkinson, John P ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CD46); Complement regulation; Hemolytic uremic syndrome; Membrane cofactor protein (MCP

Indexed keywords

COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C2; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C4B; DECAY ACCELERATING FACTOR; MONOCYTE CHEMOTACTIC PROTEIN;

ARTICLE; CHO CELL; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT DEPOSITION; COMPLEMENT SYSTEM; CYTOTOXICITY; GENE MUTATION; GENETIC TRANSFECTION; HEMOLYTIC UREMIC SYNDROME; HUMAN; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, CD46; ANTIGENS, CD55; CHO CELLS; COMPLEMENT ACTIVATION; COMPLEMENT C3; CRICETINAE; CRICETULUS; HEMOLYTIC-UREMIC SYNDROME; HUMANS; MUTATION;

EID: 57649143877     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.11.001     Document Type: Article

References (32)

1. Walport M.J. Complement. First of two parts. N Engl J Med 344 14 (2001) 1058-1066
2. Walport M.J. Complement. Second of two parts. N Engl J Med 344 15 (2001) 1140-1144
3. Lambris J.D., Ricklin D., and Geisbrecht B.V. Complement evasion by human pathogens. Nat Rev Microbiol 6 2 (2008) 132-142
4. Liszewski M.K., Farries T.C., Lublin D.M., Rooney I.A., and Atkinson J.P. Control of the complement system. Adv Immunol 61 (1996) 201-283
5. Dempsey P.W., Allison M.E., Akkaraju S., Goodnow C.C., and Fearon D.T. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271 (1996) 348-350
6. Richards A., Kavanagh D., and Atkinson J.P. Inherited complement regulatory protein deficiency predisposes to human disease in acute injury and chronic inflammatory states. Adv Immunol 96 (2008) 141-177
7. Smith R.J., Alexander J., Barlow P.N., Botto M., Cassavant T.L., Cook H.T., et al. New approaches to the treatment of dense deposit disease. J Am Soc Nephrol 18 9 (2007) 2447-2456
8. Kavanagh D., Richards A., Noris M., Hauhart R., Liszewski M.K., Karpman D., et al. Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. Mol Immunol 45 (2007) 95-105
9. Caprioli J., Noris M., Brioschi S., Pianetti G., Castelletti F., Bettinaglio P., et al. Genetics of HUS: the impact of MCP, CFH and IF mutations on clinical presentation, response to treatment, and outcome. Blood 108 (2006) 1267-1279
10. Kavanagh D., Richards A., and Atkinson J.P. Complement regulatory genes and hemolytic uremic syndromes. Annu Rev Med 59 (2008) 293-309
11. Hageman G.S., Hancox L.S., Taiber A.J., Gehrs K.M., Anderson D.H., Johnson L.V., et al. Extended haplotypes in the complement factor H (CFH) and CFH-related (CFHR) family of genes protect against age-related macular degeneration: characterization, ethnic distribution and evolutionary implications. Ann Med 38 8 (2006) 592-604
12. Edwards A.O., and Malek G. Molecular genetics of AMD and current animal models. Angiogenesis 10 2 (2007) 119-132
13. Brodbeck W.G., Mold C., Atkinson J.P., and Medof M.E. Cooperation between decay-accelerating factor and membrane cofactor protein in protecting cells from autologous complement attack. J Immunol 165 7 (2000) 3999-4006
14. Liszewski M.K., and Atkinson J.P. Membrane cofactor protein (MCP; CD46), isoforms differ in protection against the classical pathway of complement. J Immunol 156 11 (1996) 4415-4421
15. Barilla-LaBarca M.L., Liszewski M.K., Lambris J.D., Hourcade D., and Atkinson J.P. Role of membrane cofactor protein (CD46) in regulation of C4b and C3b deposited on cells. J Immunol 168 12 (2002) 6298-6304
16. Liszewski M.K., Leung M.K., and Atkinson J.P. Membrane cofactor protein (CD46): importance of N- and O-glycosylation for complement regulatory function. J Immunol 161 (1998) 3711-3718
17. Seya T., Okada M., Matsumoto M., Hong K., Kinoshita T., and Atkinson J.P. Preferential inactivation of the C5 convertase of the alternative complement pathway by factor I and membrane cofactor protein (MCP). Mol Immunol 28 (1991) 1137-1147
18. Liszewski M.K., Leung M.K., Schraml B., Goodship T.H., and Atkinson J.P. Modeling how CD46 deficiency predisposes to atypical hemolytic uremic syndrome. Mol Immunol 44 7 (2007) 1559-1568
19. Oglesby T.J., Allen C.J., Liszewski M.K., White D.J.G., and Atkinson J.P. Membrane cofactor protein (MCP; CD46) protects cells from complement-mediated attack by an intrinsic mechanism. J Exp Med 175 (1992) 1547-1551
20. Loveland B.E., Johnstone R.W., Russell S.M., Thorley B.R., and McKenzie I.F.C. Different membrane cofactor protein (CD46) isoforms protect transfected cells against antibody and complement mediated lysis. Transpl Immunol 1 (1993) 101-108
21. Lublin D.M., and Coyne K.E. Phospholipid-anchored and transmembrane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement-mediated cell damage. J Exp Med 174 (1991) 35-44
22. Kojima A., Iwata K., Seya T., Matsumoto M., Ariga H., Atkinson J.P., et al. Membrane cofactor protein (CD46) protects cells predominantly from alternative complement pathway-mediated C3-fragment deposition and cytolysis. J Immunol 151 (1993) 1519-1527
23. Devaux P., Christiansen D., Fontaine M., and Gerlier D. Control of C3b and C5b deposition by CD46 (membrane cofactor protein) after alternative but not classical complement activation. Eur J Immunol 29 (1999) 815-822
24. Seya T., and Atkinson J.P. Functional properties of membrane cofactor protein of complement. Biochem J 264 (1989) 581-588
25. Richards A., Liszewski M.K., Kavanagh D., Fang C.J., Moulton E.A., Fremeaux-Bacchi V., et al. Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Mol Immunol 44 (2007) 111-122
26. Jokiranta T.S., Zipfel P.F., Fremeaux-Bacchi V., Taylor C.M., Goodship T.J., and Noris M. Where next with atypical hemolytic uremic syndrome?. Mol Immunol 44 16 (2007) 3889-3900
27. Richards A., Kemp E.J., Liszewski M.K., Goodship J.A., Lampe A.K., Decorte R., et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci USA 100 (2003) 12966-12971
28. Servais A., Fremeaux-Bacchi V., Lequintrec M., Salomon R., Blouin J., Knebelmann B., et al. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet 44 3 (2007) 193-199
29. Fang C.J., Fremeaux-Bacchi V., Liszewski M.K., Pianetti G., Noris M., Goodship T.H.J., et al. Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis and the HELLP syndrome. Blood 111 (2008) 624-632
30. Fakhouri F., Jablonski M., Lepercq J., Blouin J., Benachi A., Hourmant M., et al. Factor H, membrane cofactor protein and Factor I mutations in patients with HELLP syndrome. Blood 112 (2008) 4542-4545
31. Edey M.M., Mead P.A., Saunders R.E., Strain L., Perkins S.J., Goodship T.H., et al. Association of a factor H mutation with hemolytic uremic syndrome following a diarrheal illness. Am J Kidney Dis 51 3 (2008) 487-490
32. Riley-Vargas R.C., Lanzendorf S., and Atkinson J.P. J Clin Invest 115 (2005) 1241-1249